Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. Among authors: nogami n. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Free article. Clinical Trial.
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Takiguchi Y, Seto T, Ichinose Y, Nogami N, Shinkai T, Okamoto H, Minato K, Seki N, Eguchi K, Kishi K, Nishikawa M, Watanabe K. Takiguchi Y, et al. Among authors: nogami n. J Thorac Oncol. 2011 Jan;6(1):156-60. doi: 10.1097/JTO.0b013e3181f7c76a. J Thorac Oncol. 2011. PMID: 21107293 Free article. Clinical Trial.
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N, Hotta K, Kuyama S, Kiura K, Takigawa N, Chikamori K, Shibayama T, Kishino D, Hosokawa S, Tamaoki A, Harita S, Tabata M, Ueoka H, Shinkai T, Tanimoto M. Nogami N, et al. Lung Cancer. 2011 Oct;74(1):80-4. doi: 10.1016/j.lungcan.2011.01.018. Epub 2011 Feb 18. Lung Cancer. 2011. PMID: 21334093 Free article. Clinical Trial.
Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Nogami N, Hotta K, Segawa Y, Takigawa N, Hosokawa S, Oze I, Fujii M, Ichihara E, Shibayama T, Tada A, Hamada N, Uno M, Tamaoki A, Kuyama S, Ikeda G, Osawa M, Takata S, Tabata M, Tanimoto M, Kiura K. Nogami N, et al. Acta Oncol. 2012 Jul;51(6):768-73. doi: 10.3109/0284186X.2011.648342. Epub 2012 Jan 27. Acta Oncol. 2012. PMID: 22283472 Clinical Trial.
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.
Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T. Okamoto I, et al. Among authors: nogami n. Invest New Drugs. 2013 Oct;31(5):1275-82. doi: 10.1007/s10637-013-9941-z. Epub 2013 Mar 10. Invest New Drugs. 2013. PMID: 23475281 Clinical Trial.
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T. Seto T, et al. Among authors: nogami n. Lancet Oncol. 2013 Jun;14(7):590-8. doi: 10.1016/S1470-2045(13)70142-6. Epub 2013 Apr 30. Lancet Oncol. 2013. PMID: 23639470 Clinical Trial.
A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
Murakami H, Yamamoto N, Shibata T, Takeda K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, Satouchi M, Kiura K, Nogami N, Endo M, Watanabe H, Tamura T. Murakami H, et al. Among authors: nogami n. Lung Cancer. 2014 Apr;84(1):67-72. doi: 10.1016/j.lungcan.2014.01.012. Epub 2014 Jan 25. Lung Cancer. 2014. PMID: 24530204 Free article. Clinical Trial.
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).
Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Harada M, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T. Takeuchi K, et al. Among authors: nogami n. Ann Oncol. 2016 Jan;27(1):185-92. doi: 10.1093/annonc/mdv501. Epub 2015 Oct 20. Ann Oncol. 2016. PMID: 26487585 Free PMC article. Clinical Trial.
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I. Takeda M, et al. Among authors: nogami n. Cancer. 2016 Apr 1;122(7):1050-9. doi: 10.1002/cncr.29893. Epub 2016 Feb 1. Cancer. 2016. PMID: 26828788 Free article. Clinical Trial.
127 results